KYTHERA files NDA for ATX-101 to reduce unwanted submental fat - 1 views
-
Alex Parker on 13 May 14US-based KYTHERA Biopharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for ATX-101 (deoxycholic acid) as an injectable treatment for the reduction of submental fat, which commonly presents as a double chin.